.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical research examines the impact of SGLT-2 inhibitors cancer risk among individuals living with type 2 diabetes. This large-scale retrospective cohort study compared patients starting sodium-glucose co-transporter 2 inhibitors (SGLT-2i) with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i). By utilizing real-world data from the TriNetX US Collaborative Network, investigators aimed to determine if these glucose-lowering agents influence obesity-associated malignancies.
Notably, the initiation of SGLT-2 inhibitors did not show a significant association with composite obesity-associated cancers compared to DPP-4i. However, the study revealed distinct findings for specific cancer types within the overall population. For instance, SGLT-2i users experienced a 22% lower rate of renal cancer. Conversely, researchers observed a 37% higher rate of thyroid cancer in the same group. Consequently, these findings suggest that the relationship between drug class and malignancy is nuanced and site-specific.
Furthermore, the analysis demonstrated modest reductions in the all-cancer outcome for the overall diabetic population. This trend remained consistent among individuals regardless of their overweight or obesity status. While the clinical significance of these overall reductions remains unclear, the potential for protective effects against certain tumors is an area for future investigation. Therefore, clinicians must balance metabolic benefits with long-term safety profiles when selecting second-line therapies.
In conclusion, while SGLT-2 inhibitors appear safe regarding the broad category of obesity-related cancers, the observed variations in renal and thyroid cancer rates warrant attention. This real-world evidence provides a deeper understanding of how modern diabetes medications interact with oncological risks in high-risk populations.
No, this large-world study found that SGLT-2 inhibitors were not associated with higher or lower rates of composite obesity-associated cancers when compared with DPP-4 inhibitors.
The study reported a lower rate of renal cancer (HR 0.78) but identified a higher rate of thyroid cancer (HR 1.37) in patients initiating SGLT-2 inhibitors compared to those on DPP-4 inhibitors.
Yes, researchers noted a modest reduction in the all-cancer outcome among the general cohort and those with overweight or obesity who initiated SGLT-2 inhibitors.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Readers should consult with a qualified healthcare professional regarding any medical concerns or treatments. Refer to the latest local and national guidelines for clinical practice.
References
Ipaye T et al. Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study. Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70562. PMID: 41749411.
Zheng J et al. Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025 Aug 07.
Wang Y et al. Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes. Drug Des Devel Ther. 2025 Dec 15.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A retrospective cohort study finds SGLT-2 inhibitors are not linked to overall obesity-associated cancers but show varying effects on renal and thyroid risk...
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
